Affordable Access

deepdyve-link
Publisher Website

[Role of VEGF in diseases of the retina].

Authors
  • Barquet, Luis Arias1
  • 1 Jefe de Sección de Retina y Vítreo, del Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Profesor Asociado de la Universidad de Barcelona, Barcelona, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España; Red Temática de Investigación Cooperativa OFTARED, Instituto de Salud Carlos III, Madrid, España. Electronic address: [email protected]
Type
Published Article
Journal
Archivos de la Sociedad Espanola de Oftalmologia
Publication Date
March 2015
Volume
90 Suppl 1
Pages
3–5
Identifiers
DOI: 10.1016/S0365-6691(15)30002-2
PMID: 25925044
Source
Medline
Keywords
License
Unknown

Abstract

Angiogenesis is the process through which new blood vessels are formed, based on preexisting vessels, and is the paradigm of diseases such as cancer and exudative ageassociated macular degeneration (ARMD). Several proangiogenic factors have been identified, such as vascular endothelial growth factor (VEGF), especially VEGF-A, which activates endothelial cells and promotes cell proliferation, migration, and an increase in vascular permeability. VEGF is also involved in the etiopathogenesis of other retinal diseases, such as diabetic macular edema and macular edema secondary to retinal vein occlusion. Likewise, there is increasing evidence that placental growth factor (PIGF) acts recepsynergetically with VEGF in promoting these diseases. Currently, the main treatment for these diseases are the anti-VEGF drugs, aflibercept, ranibizumab and bevacizumab. These agents differ in their molecular structure and mechanism of action.

Report this publication

Statistics

Seen <100 times